Respiratory Drug Delivery (RDD) - Articles and news items

Evaluating inhaler performance using idealised throats

Issue 1 2015 / 10 March 2015 / Andrew R. Martin and Warren H. Finlay, University of Alberta

The development of orally-inhaled drug products is a complex endeavour spanning multiple technical and medical fields. For the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), the inhalation delivery route permits the drug to be directly targeted to the afflicted organ, namely the lung. As such, a key characteristic of any inhaler or inhalation delivery device is the quantity of drug that is delivered to the lung each time the device is used. However, efficiently delivering a drug to the lungs is not a straightforward task; the vast majority of commercial inhalers deposit a significant amount of their emitted dose in the upper (mouth and throat) airways. Consequently, in the development of orally-inhaled drugs, limiting mouth-throat deposition is desirable both for maximising lung dose and for limiting its relative variability. However, idealised throats can support the development of inhaled drugs as this article will show….

Freeman Technology highlights relevance of the FT4 for DPI characterisation at RDD 2010

Supplier news / 11 March 2010 /

At Respiratory Drug Delivery (RDD) 2010, April 25 – 29, Florida, USA, Freeman Technology will highlight the unique insight the FT4 Powder Rheometer offers DPI formulators…

Copley Scientific to introduce new automation device for inhaled product testing at RDD 2010

Supplier news / 11 March 2010 /

Copley Scientific, sponsor of the Scientific Poster Session & Technology Exhibit at Respiratory Drug Delivery (RDD) 2010, will showcase the company’s new DUSA shaker at this event….


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...